Key Points Ruxolitinib was an effective salvage therapy for relapsed/refractory secondary hemophagocytic lymphohistiocytosis. Prolonged maintenance with a ruxolitinib taper obviated the need for intensive chemotherapy or allogeneic transplant in secondary HLH.
No takes yet. Share an insight, caveat, or question.
Goldsmith et al. (2019) studied this question.